TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20542784

Group type: EXPERIMENTAL
Intervention: MAR-tyn stent (titanium-nitride coated)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Vision stent (control group)
Number of subjects: 160
Study: 18838009

Group type: EXPERIMENTAL
Intervention: 3-month CHOICE program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30-month CHOICE program (CHOICE-plus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 0
Study: 16206354

Group type: EXPERIMENTAL
Intervention: Oral daily ibandronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent ibandronate (interval between doses > 2 mo)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium and vitamin D supplementation (placebo)
Number of subjects: 0
Study: 12161547

Group type: EXPERIMENTAL
Intervention: HLP-meal (800-kcal, containing 53% lipids, 43% proteins, 4% carbohydrates)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HCHO-meal (800-kcal, containing 89% carbohydrates, 11% proteins, 0% lipids)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HLP-meal and HCHO-meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All groups together after adjusting for body mass index
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Changes in ACTH and cortisol
Number of subjects: 30
Study: 10712711

Group type: COMPARATOR
Intervention: 3% halothane in oxygen (Group H)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 5% isoflurane in oxygen (Group I)
Number of subjects: 64
Study: 7734597

Group type: EXPERIMENTAL
Intervention: Nutrition education program volunteers
Number of subjects: 487

Group type: COMPARATOR
Intervention: Population sample
Number of subjects: 487
Study: 1645664

Group type: EXPERIMENTAL
Intervention: 99mTc‐Sestamibi
Number of subjects: 66
Study: 7011112

Group type: EXPERIMENTAL
Intervention: 30 mg reproterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30544284

Group type: EXPERIMENTAL
Intervention: Optical diagnosis including small polyps (6-9 mm)
Number of subjects: 3144

Group type: COMPARATOR
Intervention: Optical diagnosis excluding small polyps
Number of subjects: 3144
Study: 28662897

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Reductions in psychological distress
Number of subjects: 247
Study: 25491498

Group type: EXPERIMENTAL
Intervention: High-vegetable (HV) diet
Number of subjects: 88

Group type: COMPARATOR
Intervention: High-protein (HP) diet
Number of subjects: 88
Study: 24476473

Group type: EXPERIMENTAL
Intervention: Cocoa-enriched dark chocolate (DC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cocoa-depleted control (CON)
Number of subjects: 16
Study: 23015569

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 20011855

Group type: EXPERIMENTAL
Intervention: Epidural block with 10 to 15 mL of 0.5% ropivacaine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lumbar plexus block with 0.4 mL.kg(‐1) of 0.5% ropivacaine
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lumbar plexus block
Number of subjects: 41
Study: 17309918

Group type: EXPERIMENTAL
Intervention: HIF-1alpha (Ad2/HIF-1alpha/VP16) at doses of 1x10(8) to 2x10(11) viral particles
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: HIF-1alpha (Ad2/HIF-1alpha/VP16)
Number of subjects: 34
Study: 15249351

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (DM)
Number of subjects: 13105
Study: 11731907

Group type: EXPERIMENTAL
Intervention: Valeriana edulis standardized hydroalcoholic extract (450 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Valeriana officinalis extract (450 mg)
Number of subjects: 20
Study: 9506488

Group type: EXPERIMENTAL
Intervention: Thiopental (5 mg/kg)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Fentanyl (5 microg/kg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 86
Study: 7512838

Group type: EXPERIMENTAL
Intervention: G-CSF (200 microgram/m2) starting daily from 2 days before induction therapy until neutrophils recovered to above 1,500/microL or until 35 days after therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 58
Study: 2855220

Group type: EXPERIMENTAL
Intervention: Oxytocin infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6
Study: 31621884

Group type: EXPERIMENTAL
Intervention: VA‐CRAFT website
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 41
Study: 30889155

Group type: EXPERIMENTAL
Intervention: Fisionerv® gel, 3 times/day added to physiotherapy (40 minutes daily session)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Vehicle gel (placebo, 3 times/day) added to physiotherapy (40 minutes daily session)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fisionerv® gel
Number of subjects: 58
Study: 28758882

Group type: EXPERIMENTAL
Intervention: Patriarchal gender attitudes in boys
Number of subjects: 1752

Group type: EXPERIMENTAL
Intervention: Patriarchal gender attitudes in girls
Number of subjects: 1752
Study: 25814054

Group type: EXPERIMENTAL
Intervention: Standard care plus the 4-week yoga intervention (2x/week; 75 min/session) using the YOCAS©® program
Number of subjects: 167

Group type: COMPARATOR
Intervention: Standard care monitoring
Number of subjects: 167
Study: 23297841

Group type: EXPERIMENTAL
Intervention: VEN‐XR (up to 375 mg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 21783417

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) until disease progression or unacceptable toxic effects
Number of subjects: 165

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (up to four cycles)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Chemotherapy (gemcitabine plus carboplatin)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 165

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 165
Study: 19703282

Group type: EXPERIMENTAL
Intervention: Early surgical decompression (before 24 hours)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Late surgical decompression (24-72 hours)
Number of subjects: 328
Study: 17087700

Group type: EXPERIMENTAL
Intervention: Multivitamin use
Number of subjects: 3072

Group type: EXPERIMENTAL
Intervention: Individual vitamin or mineral supplement
Number of subjects: 3072

Group type: EXPERIMENTAL
Intervention: Nonvitamin/nonmineral dietary supplement (NVNMDS)
Number of subjects: 3072
Study: 15234411

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test in patients with IDCM
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Patients with IDCM
Number of subjects: 43
Study: 10932022

Group type: EXPERIMENTAL
Intervention: Prophylactic removal of third molars
Number of subjects: 200

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 200

Group type: COMPARATOR
Intervention: Retention of third molars
Number of subjects: 200
Study: 9090346

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study: 8385180

Group type: EXPERIMENTAL
Intervention: Vigorous exercise programme (three 30-min sessions a week of cycling at 60-70% of maximum workload)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Alcohol restriction (low-alcohol beer)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control light-exercise programme
Number of subjects: 75
Study: 3891456

Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study: 31266506

Group type: EXPERIMENTAL
Intervention: Lunchbox intervention
Number of subjects: 1915
Study: 28968342

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM) training (N = 23)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo training (N = 22)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No training (waitlist; N = 21)
Number of subjects: 66
Study: 25295921

Group type: EXPERIMENTAL
Intervention: Arthrodesis of the first metatarsophalangeal joint
Number of subjects: 26

Group type: COMPARATOR
Intervention: Resection of the first metatarsophalangeal joint
Number of subjects: 26
Study: 23554177

Group type: EXPERIMENTAL
Intervention: Narcissism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical attractiveness and social boldness
Number of subjects: 0
Study: 21824186

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose
Number of subjects: 6025

Group type: EXPERIMENTAL
Intervention: HbA(1c)
Number of subjects: 6025
Study: 19821105

Group type: EXPERIMENTAL
Intervention: rabdosia rubescens drop pill (960 mg) and 4 tablets of simulation agent, administered three times a day for 5 days
Number of subjects: 136

Group type: COMPARATOR
Intervention: rabdosia rubescens tablet (1000 mg) and 24 drop pills of simulation agent, administered three times a day for 5 days
Number of subjects: 136
Study: 17760546

Group type: COMPARATOR
Intervention: Placebo gel in a silica base for 2 minutes (G1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neutral EDTA conditioning agent for 2 minutes followed by placebo gel (G2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.12% CHX digluconate gel in a silica base (G3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Neutral EDTA conditioning agent for 2 minutes followed by CHX gel (G4)
Number of subjects: 80
Study: 14998597

Group type: EXPERIMENTAL
Intervention: Self-management programs
Number of subjects: 0
Study: 11172955

Group type: EXPERIMENTAL
Intervention: Central lymphatic irradiation (CLI)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Post-treatment PCR results
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: International Prognostic Index (IPI)
Number of subjects: 33
Study: 8187474

Group type: COMPARATOR
Intervention: No eating disorder at follow-up
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Severe eating disorder (anorexia or bulimia nervosa)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: NOS eating disorder diagnosis at follow-up
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Severity of eating disorder symptom severity
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Severity of psychopathology on the MMPI
Number of subjects: 59
Study: 2842405

Group type: EXPERIMENTAL
Intervention: WC3 rotavirus vaccine
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 31151390

Group type: COMPARATOR
Intervention: Arm 1 (Usual Care): 10% cash back, no weekly text, standard monthly text
Number of subjects: 2841

Group type: EXPERIMENTAL
Intervention: Arm 2: 10% cash back, generic weekly text, standard monthly text
Number of subjects: 2841
Study: 28526026

Group type: EXPERIMENTAL
Intervention: Telehealth information leaflets (THLs)
Number of subjects: 14
Study: 24499051

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 23558760

Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 40
Study: 20839291

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 18809166

Group type: EXPERIMENTAL
Intervention: 1-page informational handout
Number of subjects: 387
Study: 16844713

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (STN DBS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Intravenous levodopa infusion
Number of subjects: 18
Study: 12959805

Group type: EXPERIMENTAL
Intervention: Way-finding intervention using a location map and behavioral training technique over one month
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Way-finding intervention
Number of subjects: 32
Study: 10752492

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg at bedtime
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 21
Study: 9203718

Group type: EXPERIMENTAL
Intervention: Oral poliovirus vaccine (OPV) during NID
Number of subjects: 1288

Group type: COMPARATOR
Intervention: Unimmunized or partially immunized children
Number of subjects: 1288

Group type: COMPARATOR
Intervention: Children 0-11 months of age
Number of subjects: 1288

Group type: EXPERIMENTAL
Intervention: Television and radio as mass media
Number of subjects: 1288

Group type: COMPARATOR
Intervention: Other mass media
Number of subjects: 1288
Study: 8381091

Group type: EXPERIMENTAL
Intervention: In vivo prednisolone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Submaximal concentrations of calcium ionophore A23187 and phorbol myristate acetate stimulation
Number of subjects: 0
Study: 3079540

Group type: EXPERIMENTAL
Intervention: 4.5 X 10(6) U IFN‐beta ser i.v. daily for 10 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 90 X 10(6) U IFN‐beta ser i.v. daily for 10 days
Number of subjects: 2
Study: 30489526

Group type: EXPERIMENTAL
Intervention: Percutaneous aponeurotomy with lipofilling (PALF)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Limited fasciectomy
Number of subjects: 52
Study: 27686547

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Posterolateral Approach (PLA)
Number of subjects: 104
Study: 26300329

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Narrative Cognitive Therapy (NCT)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CBT and NCT combined)
Number of subjects: 97
Study: 23688302

Group type: EXPERIMENTAL
Intervention: Prone positioning for at least 16 hours
Number of subjects: 466

Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 466
Study: 20674902

Group type: EXPERIMENTAL
Intervention: Swim-up
Number of subjects: 53

Group type: COMPARATOR
Intervention: Density gradient centrifugation
Number of subjects: 53
Study: 18498589

Group type: EXPERIMENTAL
Intervention: Immediate loading of dental implants
Number of subjects: 10

Group type: COMPARATOR
Intervention: Early loading of dental implants
Number of subjects: 10

Group type: COMPARATOR
Intervention: Moderately rough surface implants
Number of subjects: 10

Group type: COMPARATOR
Intervention: Novel one-piece implant design
Number of subjects: 10
Study: 16536665

Group type: EXPERIMENTAL
Intervention: Alcohol (mean postdrinking blood alcohol concentration = 0.056%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alcohol and VLT play
Number of subjects: 60
Study: 12549992

Group type: EXPERIMENTAL
Intervention: Hormone therapy (not specified dosage or duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (smoking cessation, heart healthy diet, weight control, physical activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin use for control of elevated LDL cholesterol levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic blood pressure control
Number of subjects: 0
Study: 11049204

Group type: EXPERIMENTAL
Intervention: 200 microg/d selenite Se
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 200 microg/d Se-yeast
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8816210

Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy (0.5 mg/kg per day for 5 days)
Number of subjects: 26
Study: 8112809

Group type: EXPERIMENTAL
Intervention: 45 mg zinc/p.o./day as 200 mg 'zinc sulphate tablets
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (no zinc administration)
Number of subjects: 162
Study: 3755875

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 31997526

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 29
Study: 30334692

Group type: EXPERIMENTAL
Intervention: VX-445-tezacaftor-ivacaftor
Number of subjects: 2
Study: 26899786

Group type: EXPERIMENTAL
Intervention: rtfMRI‐NF training for anterior insula regulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study: 25346818

Group type: EXPERIMENTAL
Intervention: Caudal injection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transforaminal injection
Number of subjects: 30
Study: 21692827

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg kg⁻¹ infusions at weeks 0, 2, 6, 12 and 18
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg kg⁻¹ infusions
Number of subjects: 26
Study: 20601389

Group type: EXPERIMENTAL
Intervention: Losartan-based regimen
Number of subjects: 9190

Group type: EXPERIMENTAL
Intervention: Atenolol-based regimen
Number of subjects: 9190

Group type: EXPERIMENTAL
Intervention: Persistence or development of HR ≥ 84 bpm
Number of subjects: 9190

Group type: EXPERIMENTAL
Intervention: Higher in-treatment HR in time-varying multivariable Cox models
Number of subjects: 9190
Study: 18719654

Group type: EXPERIMENTAL
Intervention: Weight loss (WL; > or =5 lb loss)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Weight stable (WS; <+/‐5 lb change)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Weight regain (WR; > or =5 lb gain)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Continued weight loss
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 248
Study: 15853835

Group type: EXPERIMENTAL
Intervention: GH + 17beta-oestradiol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GH + placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 8
Study: 16285496

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 31
Study: 10858176

Group type: EXPERIMENTAL
Intervention: SAGE (Self‐Study Acceleration with Graphic Evidence), a Web‐based tutorial system
Number of subjects: 162

Group type: COMPARATOR
Intervention: Printed materials (control group)
Number of subjects: 162
Study: 8890677

Group type: EXPERIMENTAL
Intervention: Neuropsychiatric symptoms assessment
Number of subjects: 181
Study: 1815112

Group type: EXPERIMENTAL
Intervention: Interpleural block (IPB) with 10 ml 0.5% plain bupivacaine (n = 15)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Spinal analgesia with 15 mg 0.5% heavy bupivacaine and meperidine 1 mg/kg IV and diazepam 10 mg total dose (n = 10)
Number of subjects: 25
Study: 6367554

Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline
Number of subjects: 52

Group type: COMPARATOR
Intervention: D5W (control)
Number of subjects: 52
Study: 30651059

Group type: EXPERIMENTAL
Intervention: Telephone call and text message intervention provided by trained nurses
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 120
Study: 30521530

Group type: EXPERIMENTAL
Intervention: Comprehensive health facility‐ and community‐based program delivered through the HIV/AIDS program platform
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1250

Group type: EXPERIMENTAL
Intervention: Intervention facilities
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Control facilities
Number of subjects: 1250
Study: 27621395

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 (infusional fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 108

Group type: COMPARATOR
Intervention: FU/LV (infusional fluorouracil/leucovorin)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Number of subjects: 108

Group type: COMPARATOR
Intervention: FU/LV
Number of subjects: 108
Study: 25376160

Group type: EXPERIMENTAL
Intervention: Prolonged-release trazodone (150-450 mg)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 22289412

Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with complex milk lipid (11 to 12 μg/ml gangliosides)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Infant formula supplemented with complex milk lipid
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard infant formula (control group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Reference group (exclusively breast-fed infants)
Number of subjects: 29
Study: 19889508

Group type: EXPERIMENTAL
Intervention: Empowerment-based diabetes self-management support (DSMS) intervention
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control period (weekly educational newsletters)
Number of subjects: 77
Study: 18303079

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (CEEs) 0.625 mg/d for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Transdermal estradiol (E2) 0.05 mg/d for 12 weeks
Number of subjects: 27
Study: 16002420

Group type: EXPERIMENTAL
Intervention: Continuous infusion of piperacillin/tazobactam (13.5 g over 24 h)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Intermittent infusion of piperacillin/tazobactam (3.375 g every 6 h)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Both infusion methods (intermittent and continuous)
Number of subjects: 262
Study: 12466370

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study: 10364643

Group type: EXPERIMENTAL
Intervention: ApoE epsilon4 carriers
Number of subjects: 81

Group type: COMPARATOR
Intervention: ApoE epsilon4 noncarriers
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD) subjects
Number of subjects: 81

Group type: COMPARATOR
Intervention: Subjects at risk for AD (OCI and SCI)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Presence of ApoE epsilon4 allele
Number of subjects: 81